Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Friday, September 23, 2022
The DESTINY-Breast04 study reported that patients with HER2-low metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) experienced improvements in progression-free and overall survival compared with patients who received the treatment of physician’s choice. A follow-up report presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 217O) assessed patient-reported outcomes on the effects of these treatments in the hormone receptor–positive cohort. Naoto T. Ueno, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that patients treated with T-DXd maintained the global health status and quality-of-life scale score longer than patients treated with physician’s choice.
“The DESTINY-Breast04 study...was practice-changing for patients with HER2-low metastatic breast cancer,” said Dr. Ueno in an MD Anderson press release. “We know the treatment was effective, but we wanted to hear from patients themselves to better understand how patients tolerated the treatment and how it impacted their overall health.”
The study authors evaluated outcomes from patients with centrally confirmed HER2-low metastatic breast cancer with one to two prior lines of chemotherapy. Patients were randomly assigned 2:1 to receive T-DXd (n = 331) or the treatment of physician’s choice (n = 163). Patient-reported outcomes were measured using the European Organisation for Research and Treatment of Cancer quality-of-life questionnaires.
The baseline global health status score was 36.3 and 37.8 for patients treated with T-DXd and physician’s choice, respectively. The mean change from baseline for quality of life remained stable over time up to 27 cycles for patients who received T-DXd and up to 13 cycles for patients who received the treatment of physician’s choice.
The median time to definitive deterioration was 7.6 months versus 5.1 months for patients treated with T-DXd and physician’s choice, respectively. Patients treated with T-DXd reported longer times to definitive deterioration among all subscales of the quality-of-life questionnaire, including pain and physical functioning. For breast-specific symptoms, the median time to definitive deterioration was 9.8 months with T-DXd versus 5.4 months with physician’s choice.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
